<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="131193">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01990677</url>
  </required_header>
  <id_info>
    <org_study_id>ECSelsior</org_study_id>
    <secondary_id>ESCelsior2013</secondary_id>
    <nct_id>NCT01990677</nct_id>
  </id_info>
  <brief_title>Eplerenone for the Treatment of Central Serous Chorioretinopathy</brief_title>
  <official_title>Eplerenone for the Treatment of Central Serous Chorioretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the effect oral eplerenone versus placebo in patients with central serious
      chorioretinopathy  .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the effect of oral eplerenone compared to placebo in patients with central
      serous chorioretinopathy (CSCR) on sub-foveal (small part of retina) fluid using optical
      coherence tomography (OCT).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absence of sub-foveal (retinal) fluid based on spectral domain optical coherence tomography (OCT) measurement.</measure>
    <time_frame>At 1 month in acute CSCR and 2 months in chronic CSR patients</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo versus eplerenone acute CSCR patients will have sub-foveal fluid measured at month 1, and placebo versus eplerenone chronic cscr patients will be have sub-foveal fluid measured at month 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in subfoveal fluid height based on OCT measurement</measure>
    <time_frame>Month 1 for acute CSCR patients, Month 2 in chronic CSCR patients</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo versus eplerenone acute CSCR patients will be measured at month 1 and placebo versus eplerenone chronic CSCR patients will be measured at month 2.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of patients having a reduction in subfoveal fluid on OCT measurement</measure>
    <time_frame>Month  1 for acute CSCR patients and Month 2 for chronic CSCR patients.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo versus eplerenone acute CSCR patients will be measured at month 1 and placebo versus eplerenone chronic cscr patients will be measured at month 2.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Central Serous Chorioretinopathy</condition>
  <arm_group>
    <arm_group_label>25mg Eplerenone- Chronic CSCR Diagnosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 58 days. Throughout the 58 day treatment period dosage will be adjusted. The adjustment will be based on serum potassium and creatine levels from blood draws done at Day 12 and Day 33. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Chronic CSCR Diagnosis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 58 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25mg Eplerenone- Acute CSCR Diagnosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing will begin at 25mg Eplerenone taken orally , one time, each day for 28 days. Throughout the 28 day treatment period, dosage will be adjusted based on serum potassium and creatine levels from blood draws done on Day 12. From the 25 mg starting dosage, the dosage will either be increased to 50 mg a day or reduced to placebo, one time, each day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- Acute CSCR Diagnosis.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing will begin with placebo and will stay as placebo throughout the study. The placebo pills will be taken orally, once daily, for 28 days. The placebo pills will be compounded to be of similar composition to the eplerenone tablets, without the active ingredient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>25mg Eplerenone</intervention_name>
    <description>Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo</description>
    <arm_group_label>25mg Eplerenone- Chronic CSCR Diagnosis</arm_group_label>
    <arm_group_label>25mg Eplerenone- Acute CSCR Diagnosis</arm_group_label>
    <other_name>Eplerenone</other_name>
    <other_name>Inspra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo  based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.</description>
    <arm_group_label>25mg Eplerenone- Chronic CSCR Diagnosis</arm_group_label>
    <arm_group_label>Placebo- Chronic CSCR Diagnosis</arm_group_label>
    <arm_group_label>25mg Eplerenone- Acute CSCR Diagnosis</arm_group_label>
    <arm_group_label>Placebo- Acute CSCR Diagnosis.</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 and over

          -  Ability to give written informed consent

          -  Sub-retinal fluid under fovea seen on OCT

          -  Diagnosis of CSCR: classification is at the discretion of the investigator, but
             general guidelines are

               1. Acute- first episode or symptoms less than one month prior to     presentation

               2. Chronic- previously documented sub-foveal fluid, any prior treatment, symptoms
                  for over 3 months, or &lt;50% reduction in fluid thickness on OCT after 3 months.

        Exclusion Criteria:

          -  Age under 18

          -  Impaired decision-making ability

          -  At initial laboratory screening serum potassium &gt;5.5 mEq/L (milliequivalent)

          -  At initial laboratory screening serum creatinine &gt;2 mg/dL in men and &gt;1.8 mg/dL in
             women or decreased renal function by creatinine clearance less than 50 mL/min

          -  Absence of sub-foveal fluid

          -  Any patient with prior treatment for CSCR within 3 months of enrollment

          -  Patients taking potassium supplements  or potassium-sparing diuretics spironolactone,
             amiloride, and triamterene and/or potent CYP3A4 (cytochrome) inhibitors (amifostine,
             cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole,
             potassium salts,  rituximab,  tacrolimus,  voriconazole nefazodone, troleandomycin,
             clarithromycin, ritonavir, and nelfinavir)

          -  Women who are pregnant or are actively trying to conceive

          -  Patients with type 1 or type 2 diabetes
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Hsu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wills Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noga Senderowitsch</last_name>
    <email>research@midatlanticretina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Jordan</last_name>
    <email>research@midatlanticretina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Mays Landing</city>
        <state>New Jersey</state>
        <zip>08330</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Bala Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Huntingdon Valley</city>
        <state>Pennsylvania</state>
        <zip>19006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>New Wilmington</city>
        <state>Pennsylvania</state>
        <zip>19803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Newtown Square</city>
        <state>Pennsylvania</state>
        <zip>19073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>November 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Brian Burke, MPH</investigator_full_name>
    <investigator_title>Investigator</investigator_title>
  </responsible_party>
  <keyword>Central Serous Chorioretinopathy</keyword>
  <keyword>csr</keyword>
  <keyword>cscr</keyword>
  <keyword>eplerenone</keyword>
  <keyword>vision</keyword>
  <keyword>choroid</keyword>
  <keyword>retina</keyword>
  <keyword>acute</keyword>
  <keyword>chronic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Central Serous Chorioretinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
